A study of 119 breast cancers using the two most widely used assays (HercepTestTMand Ventana Pathway 4B5 assays) showed a concordance rate of 98.2% in classifying tumours as HER2-positive versus -negative. This evidence concerns the gene ERBB2 and breast carcinoma.